Jerzy Michal Dziekan

The paper identifies new drug targets in Plasmodium falciparum using thermal proteome profiling combined with molecular docking and MS-CETSA.

This study evaluates resistance development to PMX-selective and dual PMIX/X inhibitors in Plasmodium falciparum, finding that dual inhibitors have a higher resistance barrier.

This study investigates the on-target activity of plasmepsin V peptidomimetics in Plasmodium falciparum by combining chemoproteomic methods and genetic validation.

The paper identifies aryl amino acetamides that inhibit Plasmodium falciparum ring development by targeting PfSTART1, a lipid transfer protein, and shows these inhibitors block parasite transmission.

This study genetically validates PfFKBP35 as a lethal target in Plasmodium falciparum, showing its role in ribosome homeostasis and revealing non-canonical modes of action for FK506.